Novo Nordisk hopes to gain a head start over competitor Eli Lilly in terms of sales of weight loss medication in pill form. Sales campaign starts Monday. (Archive photo). Photo: Mads Claus Rasmussen/Ritzau Scanpix
Massive campaign gives Novo lead in pill race
Danish pharmaceutical company Novo Nordisk aims to outpace competitor Eli Lilly in the market for weight-loss pills by launching an aggressive sales campaign in the US. An introductory offer is available for $149 per month for the first three and a half months. Novo Nordisk received FDA approval...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?